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Anticancer effects of olive oil polyphenols and their  
combinations with anticancer drugs 
Cancer presents one of the leading causes of death in the 
world. Current treatment includes the administration of one 
or more anticancer drugs, commonly known as chemotherapy. 
The biggest issue concerning the chemotherapeutics is their 
toxicity on normal cells and persisting side effects. One 
 approach to the issue is chemoprevention and the other one 
is the discovery of more effective drugs or drug combina-
tions, including combinations with polyphenols. Olive oil 
polyphenols (OOPs), especially hydroxytyrosol (HTyr), tyro-
sol (Tyr) and their derivatives oleuropein (Ole), oleacein and 
oleocanthal (Oc) express anticancer activity on different cancer 
models. Recent studies report that phenolic extract of virgin 
olive oil may be more effective than the individual phenolic 
compounds. Also, there is a growing body of evidence about 
the combined treatment of OOPs with various anticancer 
drugs, such as cisplatin, tamoxifen, doxorubicin and others. 
These novel approaches may present an advanced strategy 
in the prevention and treatment of cancer.
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INTRODUCTION
Cancer (malignant tumor or neoplasm) develops from normal cells that have the ability 
to proliferate and grow abnormally. These cells can eventually become malignant and 
have the potential to metastasize into other tissues and organs. Cancer diseases are growing 
and causing millions of deaths worldwide, while the cancer therapy presents one of the major 
medical challenges nowadays with the continuous need for improvement in therapeutic 
approach (1–3). 
The global burden of cancer 2018 database (GLOBOCAN 2018) accessible online as a 
part of the International Agency for Research on Cancer (IARC) in 185 countries, provides 
an estimate of the incidence and mortality for 36 types of cancer. It is estimated that this 
database has grown to 18.1 million new cases and 9.6 million deaths in 2018. One out of five 
men and one out of six women worldwide develop cancer during their lifetime; one out of 
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eight men and one out of eleven women die from cancer diseases. The total number of 
survivals within the 5 years of the cancer diagnosis, called the 5-year prevalence, is esti-
mated to be 43.8 million worldwide. The top three cancer types are lung, breast and colorectal 
cancer in terms of incidence, and they are ranked among the top five in terms of mortality. 
Taken together, these three types of cancer are responsible for one-third of cancer incident 
and mortality in the world (1, 4). 
The most effective approach in the treatment of cancer is surgery combined with chemo- 
and radiotherapy. Unfortunately, tumor cells can become resistant to these therapies, due 
to the ability of cancer cells to modify drug targets, efflux chemotherapeutic drugs, increase 
the production of anti-apoptotic proteins and modulate different signal transduction path-
ways involved in carcinogenesis (5, 6). The foremost problem in cancer chemotherapy is the 
toxicity of chemotherapeutic drugs on normal cells and persisting side effects. The most 
common side effects are illness, easy bruising or bleeding, hair loss and the other, including 
nausea and vomiting neuropathy, trouble breathing, constipation and diarrhea (7). Hence, 
there is an urgent need for the discovery of newer and more effective drugs or drug combi-
nations. An alternative approach is chemoprevention, which consists of using synthetic, 
semisynthetic or natural agents to inhibit or reverse the process of carcinogenesis, parti cu-
larly in individuals with a high risk of developing cancer (8). 
In the last few years, many plant-derived polyphenols have been subject to numerous 
studies due to the beneficial effect on human health and the more studied anticancer effect. 
Some combinations of polyphenols exhibit biological activities different from those de-
tected with individual phenolic compounds (6, 9–12). Moreover, polyphenols interact addi-
tively, synergistically or antagonistically with each other, with other food components as 
well as with drugs (8, 13). Synergistic effects can be produced if they affect different targets 
or improve the solubility of each other and thereby enhance the bioavailability (14).
Several in vitro and in vivo studies have shown that the combination of natural poly-
phenols with chemotherapeutics can increase the anticancer efficacy, reduce the side effects 
of chemotherapy and overcome the chemo- or radio-resistance of cancer cells (6, 15, 16). 
Some examples of polyphenols potentially capable of sensitizing tumor cells to chemo- and 
radiotherapy through inhibition of pathways that lead to treatment resistance are genistein, 
resveratrol, silymarin, caffeic acid phenethyl ester, flavopiridol, emodin, green tea polyphe-
nols, piperine, oleandrin, ursolic acid, and betulinic acid (17–19). The use of natural poly-
phenols in combined treatment with chemotherapeutics can modulate the anticancer ef-
fects of conventional cancer treatment (20–22). In the recent years, the interest in olive oil 
polyphenols (OOPs) has significantly increased (23–26) initially because of their cardiopro-
tective effect exerted through the Mediterranean diet (MD) (27–29). European Food Safety 
Authority (EFSA) authorized the health claim that ‘olive oil polyphenols contribute to the 
protection of blood lipids from oxidative stress’ (30). These beneficial cardioprotective effects 
show significantly reduced levels of oxidized low-density lipoprotein (LDL) in plasma after 
consumption of virgin olive oil. Consequently, with the approval of this health claim, a 
global increase in the number of studies investigating the potential prevention and impro-
ve ment of health through OOPs emerged.
Olive oil (OO) phenolic compounds exert a possible chemoprotective and anticancer 
activities in different types of cancer cells (23, 31–33): breast cancer (BC) (34, 35), colon (36), 
prostate (37), melanoma (38), promyelocytic leukemia (39) and other cancer cells. Within the 
few last years, a growing interest in the collective effects of chemotherapeutics in combina-
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tion with OOPs was observed. A great number of investigations showed that olive oil phe-
nolic extract (OOPE) and individual OOPs can reduce toxic effects or modulate the activity 
of chemotherapeutics such as alkylating agents: cisplatin (CP) (40, 41), cyclophosphamide 
(42), dacarbazine (DTIC) (43); plant alkaloids: paclitaxel (44); antitumor antibiotics: mitomy-
cin C (45), doxorubicin (DOX) (46); monoclonal antibodies: trastuzumab (Tzb) (31), cetux-
imab (47); hormonal agents: tamoxifen (48); enzyme inhibitors: lapatinib (49), vemurafenib 
(43); antineoplastic and immunomodulating agents: everolimus (43) in different cancer 
models.
This review reports current knowledge about the chemoprotective and anticancer acti-
vity of OOPE and individual OOPs, particularly hydroxytyrosol (HTyr), oleuropein (Ole), 
oleacein and oleocanthal (Oc) in different types of cancer. Also, the review focuses on the 
anticancer effect of chemotherapeutics in different cancer cells in combination with OOPE 
or single OOPs (Ole, Ole aglycone, Oc, HTyr). Results of the studies incorporated in the re-
view could present a novel treatment strategy for cancer chemotherapy.
OLIVE OIL POLYPHENOLS
OO consists of a glycerol fraction making up 90–99 % of OO and of a minor non-glyce rol 
or unsaponifiable fraction (0.4–5 %) composed of at least thirty-six structurally distinct 
OOPs. They can be classified according to their similar chemical structure in the following 
groups: phenolic acids, phenolic alcohols, secoiridoids, hydroxy-isocromans, flavonoids 
and lignans (50–52). The main source of phenolic compounds is virgin olive oils.
Major OOPs (Fig. 1) include the phenolic alcohols HTyr and their secoiridoid precur-
sors: Ole, oleuropein aglycone (Ole aglycone), oleacin or Oc (53). Levels of individual phe-
nols vary due to natural variability and other factors. For example, median values of HTyr, 
oleacein, Ole aglycone and Oc obtained for 116 oil samples were 1.9, 185.7, 163.6, 30.7 mg 
kg–1, respectively (51). These OOPs are deemed to be of central importance for beneficial 
antioxidant, antiatherogenic and anti-inflammatory, antimicrobial, cardiovascular, neuro-
protective and anticancer effects that can be ascribed to the consumption of OO (24, 54).
Fig. 1. Chemical structures of major olive oil phenolic compounds used in preclinical studies as 
anticancer agents. 
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ANTICANCER EFFECTS OF OLIVE OIL POLYPHENOLS
Anticancer activities of OOPs, particularly of phenolic alcohol HTyr and secoiridoid 
polyphenols Ole and Oc, were largely investigated in the past decades and subsequently 
reviewed (23, 26, 33, 55–58) (Fig. 2). Apart from recognized potent antioxidant and anti- 
-inflammatory properties, many studies confirmed that these phenolic compounds are able 
to act on the expression of genes that control proliferation, apoptosis and differentiation of 
cancer cells (59, 60). Possible targets for anticancer effects could be genes that control the 
production of growth factors (GF) or growth factor receptors (GFR). In normal conditions, 
binding of GF to its receptor leads to the downstream activation of intracellular signaling 
mechanisms, some of them being the phosphoinositide 3-kinase (PI3K)/Akt and the mitogen- 
-activated protein kinase (MAPK) signaling pathways, important in control of cell prolife-
ration and inhibition of apoptosis (56). The over-expression of GF or GFR in cancer cells 
consequently leads to the uncontrolled proliferation and production of signaling molecules 
that promote the proliferation of neighboring cells and tumor growth (56). OOPs were 
shown to interfere with these signaling pathways, for example, they can control the 
phospho rylation state of some signaling molecules, and in that way exert their potential 
anticancer effects (33, 55, 56).
Fig. 2. Schematic panel showing the overview of major olive oil polyphenols used in preclinical studies 
in different cancer types.
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Anticancer effects of olive oil phenolic extract
The use of the OOPE instead of a single phenolic compound provides the opportunity 
for synergistic effects that could be of great interest in anticancer treatment. The anticancer 
effects of OOPE were investigated in several types of cancer cells. OOPE was shown to 
prevent from oxidative damage of deoxyribonucleic acid (DNA) in promyelocytic leukemia 
cells (HL60) (39). The concentrations of polyphenols in the extract were in the range of con-
centrations that are easily reachable after the usual intake of OO. In colorectal cancer (CRC) 
studies, OOPE showed in vitro inhibition of some crucial stages in the development of CRC, 
from initiation to promotion and metastasis (61). OOPE elicited decrease of invasion and 
spreading of HT115 colon cancer cells and the same effect was translated to the in vivo situ-
ation, with a significant decrease of tumor size and metastasis in the mouse model of CRC 
(36). Those effects were at least partially attributed to the modulation of expression of inte-
grins, cellular adhesion molecules that regulate intra- and inter-cellular signaling. In the 
mouse model of ulcerative colitis-associated CRC, extra virgin OO diet resulted in reduced 
incidence and multiplicity of tumors (62). The previous study showed no effect of OO diet 
in comparison with corn oil diet, on colon carcinogenesis in rats (63). Another in vivo study 
investigated the effects of extra virgin OO and its OOPs on gene expression of endocan-
nabinoid system components, via epigenetic regulation, in colon cancer cells and in rats fed 
with extra virgin OO (59). The results showed a selective and short-term up-regulation of 
CNR1 gene, a tumor suppressor gene encoding for type 1 cannabinoid receptor (CB1), im-
portant in the regulation of signaling pathways involved in the control of cell survival and 
apoptosis. This effect was primarily due to the content of OOPs because the changes in 
CNR1 methylation and messenger ribonucleic acid (mRNA) levels failed after treatment 
with extra virgin OO devoid of the OOPs.
Extra virgin OOPE inhibited cell proliferation in colon cancer cells with over-expressed 
estrogen receptor (ER)β, and the activation of receptors by OOPs was similar to that of 
17β-estradiol (64). Antimetastatic effects of polyphenols extracted from extra virgin OO 
were demonstrated in human transitional bladder cancer cell line T24 (65). This study indi-
cated that OOPE can significantly reduce invasion and migration of bladder cancer cells in 
vitro, probably by inhibiting matrix metalloproteinase 2 (MMP2), whose over-expression 
seems to be correlated with poor survival in different cancer types. In the same experimental 
conditions, normal urothelial fibroblasts were not significantly affected, suggesting that 
OOPE could be developed as an additional therapy for bladder cancer treatment. The inves-
tigation of extra virgin OOPE in non-melanoma skin cancers supported its possible use for 
topical applications in the prevention and treatment of this type of skin cancers (66).
Anticancer effects of HTyr, Ole, Oleacein, Oc
HTyr was widely investigated as a possible protective or therapeutic agent in CRC 
studies and in many others. Although present in relatively low concentrations in OO, HTyr 
reaches significant levels in large intestine due to the gastric digestion of OO secoiridoids 
(67). The ability of higher doses of HTyr (usually > 100 μM) to produce reactive oxygen spe-
cies (ROS), primarily H2O2, was shown to be at least in part responsible for its antiprolife-
rative and proapoptotic effect (68–70) (Fig. 2). The oxidative stress exhibited by HTyr in 
human CRC cells activated the PI3K/Akt/FOXO3a (forkhead box O3a) pathway, with the 
consequent down-regulation of the antioxidant enzymes manganese superoxide dismutase 
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(MnSOD) and catalase, but this effect was not noticed in normal colon epithelial cells (69). 
Contrary, lower doses of HTyr (< 100 μM) exerted chemo-preventive effect against H2O2-
-induced DNA damage in several types of cancer cell lines, due to its antioxidant ROS-
-scavenging activity, showing the ability of HTyr to affect the initiation step of carcinogen-
esis (70). A recent study demonstrated that the antioxidant effect of HTyr is especially 
effective in a hypoxic environment, characterized by the lower O2 pressure and higher 
levels of ROS, typical for many solid tumors (35). Furthermore, HTyr was shown to reduce 
epidermal growth factor receptor (EGFR) levels in CRC cells and in HT-29 xenografts (71). 
EGFR controls the processes important in cancer’s development, such as proliferation, 
apoptosis, angiogenesis and invasion. The activation of EGFR is followed by its rapid inter-
nalization and degradation via both lysosomal and proteasomal mechanisms. HTyr was 
able to promote EGFR degradation in cancer cells, without affecting the EGFR levels in 
normal colon cells (71).
HTyr suppressed activation of Akt, nuclear factor kappa B (NF-κB) and signal trans-
ducer and activator of transcription 3 (STAT3) signaling pathways in prostate cancer (PC) 
cell lines, all of them being important in proliferation, invasion and metastasis of cancer 
cells, and progression to aggressive castration-resistant PC (37). Suppression of Akt and 
NF-κB pathways by HTyr was also observed in the study of human hepatocellular carci-
noma (HCC), both in vitro and in vivo, in the orthotopic mouse model of human HCC (72). 
Transcription factor NF-κB, whose activation is ubiquitous in most of the malignant tu-
mors, is involved in proliferation, apoptosis, invasion, angiogenesis, metastasis and chemo-
resistance of many tumors, and therefore, this effect of HTyr could be particularly signifi-
cant. HTyr was studied in cholangiocarcinomas (CCA), a group of cancers that form in bile 
ducts and are associated with poor prognosis (73). The HTyr treatment induced apoptosis 
by multiple pathways in CCA cells and significant suppression of tumor growth in the 
mouse xenografts. This effect was due to the inhibition of extracellular signal-regulated 
kinase (ERK), another signaling pathway of crucial importance in cancer growth and deve-
lopment. The anticancer effects of HTyr were also investigated in BC (35, 74, 75), pancreatic 
cancer (76), human papillary and follicular thyroid cancer (77) and glioma (78), results that 
are worthy of further investigations.
Ole, a secoiridoid OOP, showed many beneficial anticancer properties in a great num-
ber of studies, especially in the case of BC (Fig. 2). One study showed that Ole and HTyr are 
capable of binding and activating G-protein-coupled receptor (GPER), a different type of 
ER, and cause a sustained ERK 1/2 activation leading to an apoptotic effect in ER-negative 
BC cells (75). Proapoptotic Bax protein up-regulation and a decrease in anti-apoptotic Bcl-2 
expression, together with the induction of GPER-dependent cytosolic cytochrome c release, 
revealed the mitochondrial apoptotic mechanism, which was activated by Ole and HTyr. 
Moreover, caspase-9, caspase-3 cleavage as well as peroxisome proliferator-activated recep-
tor 1 (PARP-1) inactivation supported the proposed mitochondrial apoptotic pathway. The 
same study showed the up-regulation of p21 and p53 proteins, negative regulators of the 
cell cycle, and a reduction in cyclin D1 expression after the Ole treatment (75, 79, 80). In 
another study, the proapoptotic effect of Ole via mitochondrial pathway showed more than 
10 times greater effect on ER-negative cells in comparison to ER-positive cells (79). Further-
more, Ole was able to induce the antimetastatic effect in human BC cells due to the regula-
tion of certain genes encoding for MMPs and tissue inhibitors of metalloproteinases 
(TIMPs) (60). MMP enzymes indeed facilitate the invasion of cancer cells and are respon-
467
J. Torić et al.: Anticancer effects of olive oil polyphenols and their combinations with anticancer drugs, Acta Pharm. 69 (2019) 461–482.
 
sible for distant metastases, while their inhibitors TIMPs are often decreased in cancers. 
Furthermore, Ole showed the inhibition of growth of MCF-7 human breast tumor xeno-
grafts and significant reduction of their invasiveness into the lung (81).
The first study demonstrating the effect of Ole on HT-29 colon cancer cells showed 
 induction of apoptosis by p53-dependent mechanism adapting the hypoxia-inducible factor 
1α (HIF-1α) response to hypoxia (82). HIF-1α, usually increased in many human cancers 
due to the genetic alterations and intratumoral hypoxia, was significantly decreased after 
Ole treatment. The investigation of anticancer effects of Ole in human hepatoma cells 
showed the suppression of PI3K/Akt pathway, possibly because of augmented intracellular 
ROS levels induced by Ole (83). Furthermore, Ole treatment caused the alteration in the Bax/
Bcl-2 ratio, correlated with the aforementioned apoptosis through a mitochondrial path-
way. In the case of pancreatic cancer, Ole selectively reduced the viability, caused cell cycle 
arrest and induced apoptosis via several different pathways in MiaPaCa-2 cells, without 
affecting normal pancreas cells (76).
The anticancer effects of Ole were also examined in vitro in human cervical cancer cells 
(84), PC cells (85), and neuroblastoma cells (86, 87) and in vivo in the melanoma mouse 
model (38, 88), with promising results. Two very recent studies demonstrated the beneficial 
effects of Ole in different types of lung cancers (89, 90). The diversity of Ole’s anticancer 
properties renders it a potential natural therapeutic in the future treatment of these malig-
nant diseases.
The anticancer effects of Oc were largely researched in the past decade. As a naturally 
occurring cyclooxygenase (COX) inhibitor, Oc possesses anti-inflammatory properties im-
portant for the treatment of some cancers as well (91, 92) (Fig. 2). Oc is also an inhibitor of 
hepatocyte growth factor/c-mesenchymal-epithelial transition factor (HGF/c-Met) signaling 
pathway, whose dysregulation is included in many important stages of cancer development 
and growth, some of them being cell proliferation and survival, epithelial-to-mesenchymal 
transition, angiogenesis and metastasis of cancer cells (93). Due to this activity, Oc was able 
to inhibit the proliferation, migration, and invasion of non-metastatic and highly meta-
static human BC and PC cell lines and the tumor growth in BC animal model (93, 94). Also, 
Oc treatment caused a marked down-regulation of phosphorylated mammalian target of 
rapamycin (mTOR) in metastatic BC cell line (34). Oc impaired the ability of BC cells to 
proliferate and migrate via down-regulation of TRPC6 (transient receptor potential cation 
channel) Ca2+ channel expression, in a very aggressive triple-negative type of BC (95).
Furthermore, Oc showed remarkable effects in malignant melanoma cancers. Oc was 
cytotoxic in low μM concentrations against human melanoma cells with no effect on nor-
mal dermal fibroblasts (96). In this study, both ERK and Akt phosphorylation were signifi-
cantly reduced, pointing to a possible mechanism that may lead to suppression of mela-
noma cell growth induced by Oc. In vivo study on melanoma cells showed that Oc could 
inhibit STAT3 signaling pathway, involved in apoptosis, invasion and angiogenesis of 
melanoma cells, and the tumor growth and metastases of melanoma as well (97).
Blocking of STAT3 signaling pathway by Oc was responsible for the antiproliferative 
and proapoptotic effect in HCC cells in vitro, as well as for the suppression of tumor growth 
and reduction of lung metastases in vivo (98). The anticancer effects of Oc were also demon-
strated in CRC (99) and multiple myeloma (100) cells suggesting the possible role of Oc in 
the treatment of these malignant diseases.
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The literature on anticancer effects of oleacein is not so abundant as for Hyr, Ole and 
Oc, but several cancer studies confirmed some beneficial effects worth of mentioning. In 
HL60 promyelocytic leukemia cells oleacein reduced the DNA damage when co-incubated 
in the medium with H2O2 (39). Also, oleacein and Oc separately reduced the viability and 
migration of non-melanoma skin cancer cells and inhibited proliferation of atypical keratino-
cytes stimulated with EGF. This effect was carried through the inhibition of ERK and Akt 
phosphorylation and particularly through the reduction of B-Raf expression (66) (Fig. 2). 
This study was the first evidence of the in vitro capability of oleacein to induce apoptosis in 
non-melanoma skin cancer cells through inhibition of key signaling pathway.
Much effort has been made to find or synthesize a novel OOP lipophilic derivatives 
and analogs with improved stability and enhanced biological properties (101–103). The an-
tioxidant, antiproliferative and anti-inflammatory effects of some HTyr derivatives sug-
gested a greater activity in cancer chemoprevention and preclinical treatment, in compari-
son with the parental HTyr (102). Lipophilized natural extracts containing HTyr showed an 
antiproliferative effect on the human CRC cells, with the greatest effect of HTyr-oleate frac-
tion, probably due to the major lipophilicity of the oleate chain (103). A peracetylated deri-
vative of Ole (Ac-Ole) was evaluated against thyroid tumor cell lines demonstrating sig-
nificant inhibition of cell growth (104). Ac-Ole elicited stronger effect in comparison with 
Ole, probably because of its improved permeability. In the case of BC, the antiproliferative 
effects of Ole’s peracetylated compounds were higher than Ole’s, due to a stronger antioxi-
dant activity (105). The development of semisynthetic bioisostere analogues of Oc was en-
couraged by its c-Met inhibitory activity as well as antimetastatic activity. Tyr-sinapate 
showed antimigratory, antiproliferative, and anti-invasive effects in metastatic BC without 
cytotoxicity to the normal epithelial breast cells (106). Also, another Oc-based c-Met in-
hibitor named homovanillyl sinapate showed a significant reduction in tumor growth and 
angiogenesis, without any sign of toxicity, in an orthotopic mouse model of triple negative 
BC (107).
ANTICANCER EFFECTS OF OLIVE OIL POLYPHENOLS COMBINED  
WITH ANTICANCER DRUGS
Olive oil phenolic extract combined with anticancer drugs
Numerous studies have shown that individual OOPs could interact with certain anti-
cancer drugs, thus indicating the considerable potential of the combination of OOPE and 
conventional chemotherapy in cancer treatment. These combinations may be helpful in the 
case of drug resistance and prevent or alleviate the side effects of anticancer therapy (108).
When tested in a complex mixture such as extra virgin OOPE, polyphenols have a 
stronger chemopreventive effect in comparison with individual compounds, and this effect 
may be the consequence of the synergistic effect of the components (109). However, caution 
should be required, because the combination of extra virgin OOPE and chemotherapeutic 
drugs may generate various outcomes, including synergism and antagonism.
Coccia et al. (45) have investigated the interaction of extra virgin OOPE with anticancer 
drugs paclitaxel or mitomycin C in vitro. Paclitaxel is a mitotic inhibitor indicated in the 
therapy of several types of cancer including bladder cancer (110). Mitomycin C inhibits 
DNA synthesis and it is often used in the chemotherapy of bladder cancer cells (111). Dif-
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ferent doses of mitomycin C or paclitaxel were used in the treatment of T24 cells, in the 
presence or absence of the OOPE. The data showed that OOPE reduces the antiproliferative 
ability of mitomycin C. Although 100 mg ml–1 of mitomycin C strongly increased intracel-
lular ROS production in T24 cells, the co-treatment with OOPE attenuated this effect. Op-
posite of that, OOPE strongly increased paclitaxel cytotoxicity. In the presence of the OOPE, 
5 nM paclitaxel exerted the same cytotoxicity as 100 nM paclitaxel alone. Paclitaxel alone 
did not induce oxidative stress, whereas the co-treatment with OOPE reduced basal ROS 
production. It was assumed that the increased cytotoxicity of paclitaxel could be associated 
with a change in gene expression, engaged in cell growth and proliferation, via the platelet-
activating factor (PAF) receptor signaling or PI3K signaling (45).
Olive oil polyphenols combined with anticancer drugs
The influence of OO characteristic phenolic compounds, Ole, Oc, Ole aglycone and 
HTyr on the effects of conventional anticancer drugs attracts a great deal of attention nowa-
days (26). There are a few studies concerning the effects of combined treatment with Ole 
and CP on CP-induced toxicities. CP belongs to the first generation of anticancer drugs, and 
it is widely used in the chemotherapy of many cancers. Despite its effectiveness, the major 
limitations of CP use in therapy are serious side effects as the development of drug-resis-
tance and acute nephrotoxicity, noticed in 20–30 % of patients (112). Renal injury is the 
consequence of oxidative and inflammatory processes. Concomitant use of various natural 
compounds with antioxidant and anti-inflammatory properties have been proposed for the 
prevention. It was shown that Ole attenuates CP-induced acute renal injury in a male 
BALB/c mouse model (40) (Table I). In this study the mice were divided in six groups: con-
trol group, a group treated with Ole alone (20 mg kg–1, orally), a group treated with CP alone 
(13 mg kg–1, intraperitoneally (i.p.)), and three groups treated firstly with CP, and after 48 
hours with Ole (5, 10, 20 mg kg–1) for two days. The kidney tissue of the groups treated with 
CP alone, CP+Ole and control group were compared. In the control group and the CP+Ole 
group, normal kidney morphology was observed, whereas in the group treated with CP 
there was tubular necrosis. According to biochemical parameters, the protective effect of 
Ole was connected to the decreased ERK 1/2 activation and ERK-dependent inflammatory 
response, apoptosis and antioxidant enzyme expression. 
Another study analyzed the combined treatment with Ole and CP in human HCC 
HepG2 cells (41). The first line of cells were treated with CP alone (20, 50 and 100 μM), the 
second line with Ole alone (100, 200, 300 and 400 μM) and the third line with the combina-
tion of CP (50 μM) and Ole (100, 200, 300 and 400 μM). Gene expression of nerve growth 
factor (NGF), MMP-7, caspase-3, the concentration of NO, NGF and pro-NGF were com-
pared. In cells treated with CP+Ole, the toxic effects were reduced, and the most effective 
combination was with 200 μM Ole (41). Also, the effect of Ole on CP-induced liver damages 
in male Sprague-Dawley rats was investigated (113). Control group was treated with CP 
alone for 24 h (7 mg kg–1 day–1, i.p.), three groups were treated with Ole alone for three days 
(50, 100, and 200 mg kg–1, i.p.), and three groups were treated with the combination of CP 
and Ole, CP (7 mg kg–1 day–1, i.p.) and after 24 hours Ole (50, 100, and 200 mg kg–1, i.p.). In the 
group treated with CP alone, the whole liver tissue showed significant histological damages, 
increased incidence of oxidative stress, the induction of 8-hydroxy-2′-deoxyguanosine 
(8-OHdG), and abnormal results on liver function tests. Administration of Ole alleviated 
liver injury and the biochemical parameters reached the normal values. The dose of 200 mg 
470
J. Torić et al.: Anticancer effects of olive oil polyphenols and their combinations with anticancer drugs, Acta Pharm. 69 (2019) 461–482.
 
Table I. Olive oil polyphenols and their combinations with anticancer drugs in preclinical cancer models
Phenolic 
compounds Anticancer drug Experimental models Effects of OOPs References
OOPE
Paclitaxel




Mitomycin C Reduced drug cytotoxicity
Ole Cisplatin Male BALB/c mouse model Renoprotective (40)
Ole Cisplatin Male Sprague-Dawley rats Liver protective (113)
Ole Cisplatin Hepatocellular carcinoma cells
Reduction of toxic 
effect (41)
Ole Cisplatin Sprague-Dawley rats Stomach and lung protective (114)
Ole Cisplatin Sprague-Dawley rats Pancreas protective (115)
Ole or HTyr Cisplatin Water solution
Form conjugate with 
drug in water 
solution
(116)
Ole aglycone Trastuzumab Human breast cancer cells (SKBR3) Synergistic (31)
Oc Tamoxifen Luminal breast cancer cells (HER-2 positive BT474) Synergistic (48)
Oc Lapatinib Breast cancer cells (HER-2 positive BT474 and SKBR3) Synergistic (49)
HTyr Paclitaxel
Breast cancer cells 
(MCF-7, MDA-MB-231)
Synergistic (44)




Human breast cancer cells 




Colon cancer cells 
(HT-29 and WiDr)









Ole or QT Cyclo-phosphamide Male Winstar rats
Reduced drug 
cytotoxicity (42)
Ole 2-metoxyestradiol Human osteosarcoma cells Synergistic (117)
kg–1 showed the optimal protective effect. The same experimental design was used to test 
the effects of combined treatment of Ole and CP on stomach and lung injuries induced by 
CP (114) and CP-induced pancreas toxicity (115). It was shown that the addition of a high 
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dose of Ole to animals treated with CP exerts a protective effect. CP increased 8-OHdG, 
malondialdehyde (MDA) and total oxidative stress (TOS) and also caused severe tissue 
damages, while Ole (200 mg kg–1) decreased these parameters and improved tissue dam-
ages. In addition, the interaction between Ole and HTyr with hydrated CP was investigated 
by the use of reverse-phase liquid chromatography coupled to electrospray ionization and 
mass spectrometry (RPLC-ESI-MS) and by MS/MS measurements (116). Hydrated CP is the 
active form of CP, with labile chloride ligands in CP complex exchanged by water. This 
complex binds to DNA purine base forming adduct which inhibits transcription and fi-
nally kills the cancerous cell. This study shows that Ole or HTyr and hydrated CP form 
conjugate in water solution, what could be of interest when considering the mechanisms by 
which they might contribute to reducing CP-induced toxicity (116).
Besides the effect of Ole on CP therapy, the effects of combined treatment of other 
OOPs with various anticancer agents were also studied. Among the first combinations was 
the one of Ole aglycone with trastuzumab (Tzb), the monoclonal antibody (31). The study 
was conducted in the human SKBR3 BC cell line characterized by human epidermal growth 
factor receptor 2 (HER-2) expression. HER-2 is a proto-oncogene with an important role in 
cancer development and treatment failure in BC disease. Tzb blocks HER-2 expression and 
activity by reduction of HER-2 extracellular domain cleavage and its subsequent autophos-
phorylation. In this study the same mechanism was reported for Ole aglycone, and also the 
synergistic Tzb and Ole aglycone activity. Ole aglycone enhanced Tzb-induced down-regu-
lation of HER-2 expression and induced up to a 50-fold increase in the efficacy of Tzb. A cell 
line with acquired autoresistance to Tzb (SKBR3/Tzb100 cells), treated with Ole aglycone, 
led to the recovery of the Tzb sensitivity. This is of importance to circumvent Tzb resistance 
in BC disease and could be of clinical relevance.
The combined treatments of phenolic compound Oc and anticancer drugs used in BC 
therapies was studied. Among them was the combination of Oc and anti-estrogen tamoxi-
fen (Tmx), investigated in a luminal BC cell line (BT474), characterized by HER-2 expression 
and, estrogen and progesterone receptors (48). Luminal BCs account for about 60 % of all 
BCs. Conventional treatment for luminal B tumors is anti-HER-2 and endocrine therapy, 
although luminal B tumors show resistance to anti-HER-2 targeted therapies and reduced 
sensitivity to endocrine treatment. In this study, Oc and Tmx act synergistically probably 
due to their different binding modes at the ERs site. Another investigated combination was 
Oc and lapatinib (49). Combined treatment with Oc and lapatinib was studied in HER-
-2-positive BT-474 and SK-BR-3 BC cell lines. Lapatinib is an EGFR/HER-2 inhibitor for HER-
-2-amplified BC. Dysregulation of EGFR/HER-2 family is a feature of aggressive BC, while 
the anticancer activity of Oc is associated with c-Met. The combined treatment elicited the 
synergistic anti-proliferative effect, compared to Oc or lapatinib monotherapy. The combi-
nation significantly inhibited EGFR, HER-2, and c-Met receptor activation, as well as down-
stream signaling proteins, and inhibited invasion and migration of BC cells. Oc (10 mg 
kg–1) and lapatinib (12.5 mg kg–1) suppressed more than 90 % of BT-474 tumor cells growth, 
compared to Oc or lapatinib monotherapy. The future potential of combination therapy was 
suggested as it sensitizes HER-2-overexpressing BCs and significantly reduces required 
doses of targeted HER family therapeutics. Recently, the combination of HTyr and pacli-
taxel was studied in in vitro and in vivo BC models (44). Paclitaxel generates a very high re-
dox imbalance, promoting damage to both tumor and healthy cells. The impact of the com-
bination of HTyr and paclitaxel on proliferation rates was assayed in MCF-7 and 
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MDAMB-BC cell lines. The combined treatment was more efficient than paclitaxel alone. In 
vivo model of BC, female Sprague-Dawley rats with chemically 7,12-dimethylbenz(a)anthra-
cene (DMBA) induced cancer, characterized by estrogen overexpression, was treated for 6 
weeks to test the effect of this combination. In the case of combined treatment, the tumor 
volume was significantly reduced in comparison with paclitaxel alone. The combination 
improved the antioxidant status and in that way compensated the adverse effects. This 
combination possibly allows lower drug doses, with reduced side effects. Another study 
investigated the effects of the combination of Ole and DOX on breast tumor xenografts in 
in vitro and in vivo models (46). Female nude mice were injected subcutaneously with hu-
man BC cells MDA-MB231. After the growth of tumors, the animals were divided into 4 
groups: a control group, a group treated with Ole (50 mg kg–1), a group treated with DOX 
(2.5 mg kg–1) and a group treated with the combination of DOX (1.5 mg kg–1), immediately 
followed by Ole (50 mg kg–1). A xenograft tumor was characterized by low or no expression 
of HER-2, estrogen and progesterone. In the group with combined treatment, a more than 
3-fold decrease in the volume of the tumor was observed. The effect was connected with 
the mitochondrial pathway and the induction of apoptosis.
The effect of the combination of HTyr and anticancer drug cetuximab was studied in 
colon cancer in vitro model (47). The growth of colon tumors, as well as several other epi-
thelial human cancers of the digestive tract, is connected with signaling pathways trig-
gered by EGF. HTyr down-regulates EGF receptor (EGFR) expression and cell proliferation 
in colon cancer cells, similarly as cetuximab, monoclonal antibody currently used in the 
treatment of colon cancers. The effects of combined treatment with HTyr and cetuximab 
were investigated in HT-29 and WiDr colon cancer cells. The combination reduced cell 
proliferation at a concentration 10 times than the one used as monotherapy. The combined 
treatment induced a marked down-regulation of EGFR levels, and mitochondrial dysfunc-
tion leading to cell cycle arrest and apoptosis, but to a very small extent affected the normal 
human colon and skin cells, suggesting that the combined therapy might attenuate cetu xi mab 
side effects, as skin toxicity and diarrhea.
The effects of combined treatment with Ole and conventional drugs used to treat BRAF 
melanoma were also investigated (43). Melanoma is the major cause of skin cancer-related 
deaths and about 50–60 % of melanomas show the BRAF mutation, which implies the acti-
vation of ERK signaling, leading to an increase of proliferation and transformation. The 
effect of combined treatment was analyzed in A375 human melanoma cells. Ole increased 
the cytotoxic effect of DTIC, which is considered the main drug for the treatment of the 
advanced stage of melanoma, at 250 μM concentration, and potentiated the effect of evero-
limus (RAD001), possibly through the inhibition of the pAKT/pS6 pathway, while it showed 
no effect on vemurafenib (PLX4032) at a 250 μM concentration. 
Ole and quercetin (QT) combination with cyclophosphamide (Cyclo) in Cyclo-induced 
hepatotoxicity in male Wistar rats was investigated (42). Cyclo is a cytotoxic oxazaphospho-
rine alkylating agent that requires activation in the liver. It has been used in the therapy of 
a variety of cancers, especially lymphoma, and also as an immunosuppressive drug, with 
serious side effects, as hepatotoxicity. In the rat group which received Cyclo alone, alkaline 
phosphatase, serum transaminase, tumor necrosis factor-alpha (TNF-α) and hepatic MDA 
were significantly increased, superoxide dismutase (SOD) and hepatic reduced glutathione 
catalase levels were significantly reduced, hepatic nuclear factor erythroid 2-related factor 
2 (Nrf2) and heme oxygenase-1 (HO-1) expressions were down-regulated and reduction in 
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hepatic nuclear Nrf2 binding activity and hepatic tissue damage were observed. In rat 
groups which were treated with combined therapy, Cyclo+Ole or Cyclo+QT, both Ole and 
QT exhibited an improvement in the biochemical and histopathological findings, connected 
with attenuation of oxidative stress and inflammation, via Nrf2/HO-1 signaling pathway.
A recent study analyzed the effects of combined treatment with Ole and 2-methoxy-
estradiol (2-ME), in highly metastatic osteosarcoma (OS) cells, 143B OS (117). Ole exerts 
anti-migratory and anti-proliferative effects on human OS cells. In the case of treatment 
with Ole alone and in combination with 2-ME, the induction of autophagy and/or induction 
of nitro-oxidative stress was observed.
The reduced effectiveness of chemotherapeutics is attributed, among others, to their 
inappropriate pharmacokinetic features as poor penetration into the tumor microenviron-
ment and toxicity to healthy cells. One approach which tries to resolve this problem is the 
development of targeted nanotherapeutics (118). The formulation of co-encapsulated QT, a 
flavonoid present in OO, with Tmx in orally administrable poly(lactic-co-glycolic acid)-
nanoparticles (PLGA-NPs) showed significantly higher tumor suppression in comparison 
to the treatment with QT or Tmx alone, but also to their combination, in DMBA induced BC 
model in female rats (119). This could be a promising perspective when considerating com-
bined treatments with OOPs and anticancer drugs.
CONCLUSIONS
An ideal drug for cancer chemotherapy must exhibit high levels of cytotoxicity with 
negligible side effects. The results of in vitro and in vivo studies reported that OOPs have a 
high potential as chemopreventive and anticancer agents. A combination of OOPs with 
anticancer drugs may offer a better strategy for cancer treatment, due to the improvement 
of chemotherapy efficacy and reduction of toxic effects. Although the described preclinical 
studies confirm the beneficial effects of OOPs alone and combined with anticancer drugs, 
their efficacy remains to be proven in humans. 
Abbreviations, acronyms, symbols. – 2-ME – 2-methoxyestradiol, 8-OHdG – 8-hydroxy-2′-
deoxyguanosine, BC – breast cancer, CB1 – cannabinoid receptor, CCA – cholangiocarci-
noma, c-Met – mesenchymal-epithelial transition factor, COX – cyclooxygenase, CP – cis-
platin, CRC – colorectal cancer, Cyclo – cyclophosphamide, DMBA – 7,12-dimethylbenz(a)
anthracene, DNA – deoxyribonucleic acid, DOX – doxorubicin, DTIC – dacarbazine, EFSA 
– European Food Safety Authority, EGF – epidermal growth factor, EGFR – epidermal 
growth factor receptor, ER – estrogen receptor, ERK– extracellular signal-regulated kinase, 
FOXO3a – forkhead box O3a, GF – growth factor, GFR – growth factor receptor, GLOBO-
CAN 2018 – global burden of cancer 2018 database, GPER – G-protein-coupled receptor, 
HCC – hepatocellular carcinoma, HER-2 – human epidermal growth factor receptor 2, HGF 
– hepatocyte growth factor, HIF-1α – hypoxia-inducible factor-1α, HO-1– heme oxygenase-1, 
HTyr – hydroxytyrosol, i.p. – intraperitoneally, IARC – International Agency for Research 
on Cancer, MAPK – mitogen activated protein kinase, MD – Mediterranean diet, MDA – 
malondialdehyde, MMP – matrix metalloproteinase, MnSOD – manganese superoxide dis-
mutase, mRNA – messenger ribonucleic acid, mTOR – mammalian target of rapamycin, 
NF-κB – nuclear factor kappa B, NGF – nerve growth factor, Nrf2 – nuclear factor erythroid 
2-related factor 2, Oc – oleocanthal, Ole – oleuropein, Ole aglycone – oleuropein aglycone, 
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OO – olive oil, OOP – olive oil polyphenol, OOPE – olive oil phenolic extract, OS – osteosar-
coma, PAF – platelet-activating factor, PARP-1 – peroxisome proliferator-activated receptor 
1, PC – prostate cancer, PI3K – phosphoinositide 3-kinase, PLGA-NPs – poly(lactic-co-gly-
colic acid)-nanoparticles, QT – quercetin, ROS – reactive oxygen species, SOD – superoxide 
dismutase, STAT3 – signal transducer and activator of transcription 3, TIMP – tissue inhi-
bitor of metalloproteinase, Tmx – tamoxifen, TNF-⍺ – tumor necrosis factor-alpha, TOS – 
total oxidative stress, TRPC6 – transient receptor potential cation channel, Tyr – tyrosol, 
Tzb – trastuzumab.
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